<DOC>
	<DOCNO>NCT00260884</DOCNO>
	<brief_summary>- OBJECTIVES To determine prospective randomize clinical trial , effect extend lymph node dissection ( R3 gastrectomy ) versus conventional surgery ( R0/1 gastrectomy ) tumor recurrence survival Chinese patient advance cancer stomach ( adenocarcinoma invasion beyond submucosa ) . - STATISTICAL CONSIDERATIONS The major end point disease free survival survival . The log-rank test use analytic method disease-free survival overall durvival . The follow-up time treatment five year . Previous experience provide estimation 20 % 5-year survival rate conventional surgery gastric cancer . Assuming new treatment ( radical surgery ) may increase 5-year survival rate 40 % , estimate 118 evaluable patient require detected significance 0.05 level power 0.8 use one tailed test . We expect enter 50 patient per year finish accrual patient within 2.5 year .</brief_summary>
	<brief_title>Phase III Study OF Gastric Surgery Advanced Stage Gastric Cancer</brief_title>
	<detailed_description>* TREATMENT PLAN Patients randomize intraoperatively arm I ( conventional [ R0/R1 ] gastrectomy ) arm II ( extended radical [ R3 ] lymph node dissection ) . Arm I : Resection stomach , great omentum , less omentum , adjacent organ ( ) primary tumor invade directly . A total distal subtotal gastrectomy decide proximal distance cardia tumor . A margin 3 cm require well-defined ( Borrmann I II ) tumor , 5 cm ill-defined ( Borrmann III IV ) tumor . When total gastrectomy perform , distal pancreas spleen preserve unless direct invasion organ . The left gastric artery ligate origin distal bifurcation ascend descend branch . Arm II : The procedure Arm I , additionally , extend lymph node dissection include dissection N1 , N2 N3 node . These group ( N ) comprise lymph node station depend location primary tumor ( Fig . 1 ) . 1 . For N2 dissection , leave gastric artery ligate origin facilitate dissection No.7 . If total gastrectomy indicate , splenectomy essential dissection station No . 10 , distal pancreatectomy dissection station No.11 . Combined resection adjacent organ perform distal subtotal gastrectomy . 2 . If primary cancer locate middle low third stomach , No.1 ( node right cardiac ) 11 ( node along splenic artery ) excise routinely frozen section gastric resection . If cancer metastasis see No.1 11 lymph node perform . If No . 1 lymph node positive cancer metastasis , total gastrectomy perform instead distal subtotal resection . If No . 11 lymph node positive , splenectomy distal pancreatectomy perform addition radical resection stomach lymph node . 3 . For N3 dissection : No . 12 ( nodes hepatoduodenal ligament ) , No . 13 ( node retropancreatic region ) No . 14 ( node root mesentery ) dissect . For patient gastric cancer recurrence gastrectomy , chemotherapy cisplatin、 5-FU、Leucovorin give . Cisplatin 20mg/m2 5-FU 450 mg/m2 Leucovorin 90 mg/m2 The three drug give 500ml normal saline infuse intravenously simultaneously 96 hour repeat every 3 week . ( 21days ) Dose modification： Delay treatment one week ( WBC &lt; 4000/dl immediately treatment ) . Reduce dose subsequent cycle 5-FU 20 % WBC nadir &lt; 1000/dl . Delay treatment one week ( oral mucositis diarrhea immediately treatment ) . Reduce dose subsequent cycle 5-FU 10 % grade 2 20 % grade 3 4 mucositis diarrhea . Stop treatment grade 4 non-hematological toxicity . Stop cisplatin treatment serum creatinine &gt; 2mg/dl . Duration treatment： Continue treatment patient disease progression . * DATA AND PROTOCOL MANAGEMENT 10.1 Registration , randomization perform Cancer Clinical Trial Operations Office call 789-9046 . ( 47 ) &amp; 7852459 . Quality control data perform Cancer Clinical Trial Operations Office , Institute Biomedical Sciences , Academia Sinica . Data evaluate statistician study chairman data analyze 10.2 Protocol Compliance : attending physician oncology research nurse must see patient prior treatment follow ensure investigation , treatment procedure data record do record accord protocol .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Patients histologically proven adenocarcinoma stomach . 2 . No clinical early stage stomach cancer ( mucosa submucosal invasion ) . 3 . No esophageal invasion . 4 . No distant metastatic disease . 5 . No paraaortic , macrolymphadenopathy 6 . No N3 , macrolymphadenopathy 7 . Suitable gastric surgery curative intent . 8 . Medically fit surgery . 9 . No emergency resection require . 10 . No previous gastrectomy . 11 . Not old 75 year . 12 . Signed informed consent form . 13 . No previous concomitant cancer . 1 . Patients adenocarcinoma stomach . 2. distant metastatic disease . 3. previous gastrectomy . 4. old 75 year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>